Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Metal-specific CD4+ T-cell responses induced by beryllium exposure in HLA-DP2 transgenic mice.

Falta MT, Tinega AN, Mack DG, Bowerman NA, Crawford F, Kappler JW, Pinilla C, Fontenot AP.

Mucosal Immunol. 2016 Jan;9(1):218-28. doi: 10.1038/mi.2015.54. Epub 2015 Jul 1.

2.

Structural basis of chronic beryllium disease: linking allergic hypersensitivity and autoimmunity.

Clayton GM, Wang Y, Crawford F, Novikov A, Wimberly BT, Kieft JS, Falta MT, Bowerman NA, Marrack P, Fontenot AP, Dai S, Kappler JW.

Cell. 2014 Jul 3;158(1):132-42. doi: 10.1016/j.cell.2014.04.048.

3.

Identification of multiple public TCR repertoires in chronic beryllium disease.

Bowerman NA, Falta MT, Mack DG, Wehrmann F, Crawford F, Mroz MM, Maier LA, Kappler JW, Fontenot AP.

J Immunol. 2014 May 15;192(10):4571-80. doi: 10.4049/jimmunol.1400007. Epub 2014 Apr 9.

4.

T cell recognition of beryllium.

Dai S, Falta MT, Bowerman NA, McKee AS, Fontenot AP.

Curr Opin Immunol. 2013 Dec;25(6):775-80. doi: 10.1016/j.coi.2013.07.012. Epub 2013 Aug 23. Review.

5.

T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex.

Adams JJ, Narayanan S, Liu B, Birnbaum ME, Kruse AC, Bowerman NA, Chen W, Levin AM, Connolly JM, Zhu C, Kranz DM, Garcia KC.

Immunity. 2011 Nov 23;35(5):681-93. doi: 10.1016/j.immuni.2011.09.013.

6.

Mutagenesis of beryllium-specific TCRs suggests an unusual binding topology for antigen recognition.

Bowerman NA, Falta MT, Mack DG, Kappler JW, Fontenot AP.

J Immunol. 2011 Oct 1;187(7):3694-703. doi: 10.4049/jimmunol.1101872. Epub 2011 Aug 26.

7.

Linking genetic susceptibility and T cell activation in beryllium-induced disease.

Falta MT, Bowerman NA, Dai S, Kappler JW, Fontenot AP.

Proc Am Thorac Soc. 2010 May;7(2):126-9. doi: 10.1513/pats.201002-022RM. Review.

8.

Cutting edge: inhibitory effects of CD4 and CD8 on T cell activation induced by high-affinity noncognate ligands.

Chervin AS, Stone JD, Bowerman NA, Kranz DM.

J Immunol. 2009 Dec 15;183(12):7639-43. doi: 10.4049/jimmunol.0901664.

9.

Different strategies adopted by K(b) and L(d) to generate T cell specificity directed against their respective bound peptides.

Bowerman NA, Colf LA, Garcia KC, Kranz DM.

J Biol Chem. 2009 Nov 20;284(47):32551-61. doi: 10.1074/jbc.M109.040501. Epub 2009 Sep 15.

10.

Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity.

Bowerman NA, Crofts TS, Chlewicki L, Do P, Baker BM, Christopher Garcia K, Kranz DM.

Mol Immunol. 2009 Sep;46(15):3000-8. doi: 10.1016/j.molimm.2009.06.012.

11.

Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells.

Thomas DL, Kim M, Bowerman NA, Narayanan S, Kranz DM, Schreiber H, Roy EJ.

J Immunol. 2009 Aug 1;183(3):1828-37. doi: 10.4049/jimmunol.0802322. Epub 2009 Jul 10.

12.

Equilibrium between host and cancer caused by effector T cells killing tumor stroma.

Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, Rowley DA, Schreiber H.

Cancer Res. 2008 Mar 1;68(5):1563-71. doi: 10.1158/0008-5472.CAN-07-5324.

13.

How a single T cell receptor recognizes both self and foreign MHC.

Colf LA, Bankovich AJ, Hanick NA, Bowerman NA, Jones LL, Kranz DM, Garcia KC.

Cell. 2007 Apr 6;129(1):135-46.

14.

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.

Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, Kranz DM, Schreiber H.

J Exp Med. 2007 Jan 22;204(1):49-55. Epub 2007 Jan 8.

Supplemental Content

Loading ...
Support Center